Oramed Pharmaceuticals (Israel) Performance
| ORMP Stock | 8.63 0.02 0.23% |
The company holds a Beta of -0.77, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Oramed Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Oramed Pharmaceuticals is likely to outperform the market. At this point, Oramed Pharmaceuticals has a negative expected return of -0.0574%. Please make sure to check Oramed Pharmaceuticals' standard deviation, jensen alpha, and the relationship between the coefficient of variation and information ratio , to decide if Oramed Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Oramed Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Oramed Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Quick Ratio | 5.02 | |
| Fifty Two Week Low | 1,074.00 | |
| Fifty Two Week High | 1,074.00 |
Oramed |
Oramed Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 894.00 in Oramed Pharmaceuticals on August 31, 2024 and sell it today you would lose (31.00) from holding Oramed Pharmaceuticals or give up 3.47% of portfolio value over 90 days. Oramed Pharmaceuticals is generating negative expected returns and assumes 1.8933% volatility on return distribution over the 90 days horizon. Simply put, 16% of stocks are less volatile than Oramed, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Oramed Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oramed Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oramed Pharmaceuticals, and traders can use it to determine the average amount a Oramed Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0303
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ORMP |
Estimated Market Risk
| 1.89 actual daily | 16 84% of assets are more volatile |
Expected Return
| -0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Oramed Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oramed Pharmaceuticals by adding Oramed Pharmaceuticals to a well-diversified portfolio.
Oramed Pharmaceuticals Fundamentals Growth
Oramed Stock prices reflect investors' perceptions of the future prospects and financial health of Oramed Pharmaceuticals, and Oramed Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oramed Stock performance.
| Return On Equity | -78.51 | |||
| Return On Asset | -26.77 | |||
| Operating Margin | (584.92) % | |||
| Current Valuation | 156.33 M | |||
| Shares Outstanding | 17.38 M | |||
| Price To Book | 866.13 X | |||
| Revenue | 2.64 M | |||
| EBITDA | (15.43 M) | |||
| Cash And Equivalents | 26.19 M | |||
| Cash Per Share | 1.51 X | |||
| Book Value Per Share | 1.24 X | |||
| Cash Flow From Operations | (14.32 M) | |||
| Earnings Per Share | (0.87) X | |||
About Oramed Pharmaceuticals Performance
By analyzing Oramed Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Oramed Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Oramed Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oramed Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York. ORAMED PHARMA is traded on Tel Aviv Stock Exchange in Israel.Things to note about Oramed Pharmaceuticals performance evaluation
Checking the ongoing alerts about Oramed Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oramed Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oramed Pharmaceuticals generated a negative expected return over the last 90 days | |
| Oramed Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 2.64 M. Net Loss for the year was (15 M) with profit before overhead, payroll, taxes, and interest of 2.54 M. | |
| Oramed Pharmaceuticals has accumulated about 26.19 M in cash with (14.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51. |
- Analyzing Oramed Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oramed Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Oramed Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oramed Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oramed Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oramed Pharmaceuticals' stock. These opinions can provide insight into Oramed Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Oramed Stock analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |